Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$2.27 USD
-0.08 (-3.40%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.24 -0.03 (-1.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SNTI 2.27 -0.08(-3.40%)
Will SNTI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNTI
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
SNTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Other News for SNTI
Senti Biosciences Inc trading halted, news pending
Senti Bio Announces Reverse Stock Split
Senti Bio announces 1-for-10 reverse stock split
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Why Is Faraday Future (FFIE) Stock Down 27% Today?